Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-06-05

Clinical Trial Update: A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years [Phase 3]

View source ↗

Summary

Phase 3 trial update for ExPEC9V vaccination aimed at preventing invasive ExPEC disease in older adults with recent urinary tract infections; study status: comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ExPEC9V (9-valent ExPEC vaccine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | Phase 3 | Status: COMPLETED